The authors criticize regulatory bodies (e.g., Danish DTU) for alleged bias and lack of transparency, yet their own conflict of interest statement reveals a significant industry affiliation.
Question 1: Terrence Lemerond is the founder of EuroPharma USA Inc., a company that produces and sells herbal dietary supplements, including adaptogens. Alexander Panossian has received funding from EuroPharma USA Inc. to develop herbal medical products. Given that the paper repeatedly argues against regulatory restrictions on adaptogens (e.g., ashwagandha) and advocates for their broader acceptance, how can readers be assured that the conclusions are not directly influenced by the authors’ financial interests in the commercial success of these products? This appears to be a classic case of the very “conflict of interest” the paper critiques in others.
Question 2: The paper criticizes the Danish DTU report for lacking peer review and transparency but does not state whether this narrative review itself underwent rigorous peer review beyond standard journal processes. Given the strong advocacy tone and potential financial conflicts, why should the scientific community trust this review as an unbiased assessment?